Mounjaro Non-Responder Profile: Who Does Not Lose Weight on Tirzepatide?

Published Jan 28, 2025Updated Sep 30, 2026Last reviewed Jan 28, 2025

14 linked public sourcesEditorial, sourcing, and corrections policy

Some people lose little weight on tirzepatide, but a slow first few weeks does not identify a permanent non-responder. The useful assessment combines percentage weight change, time at the prescribed dose, missed treatment, tolerability and the reason the medicine was prescribed. A plateau after substantial weight loss is also different from little change since treatment began. [1,2]

Mounjaro and Zepbound contain tirzepatide. In the United States, Mounjaro is used in type 2 diabetes care, while Zepbound has a weight-management indication. For someone taking Mounjaro for diabetes, glucose control and other treatment goals remain part of the review even when weight changes less than expected. [3,4]

How many people lose less than 5%?

In SURMOUNT-1, 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, were randomized to tirzepatide or placebo for 72 weeks. The published treatment-regimen analysis reported the following results. [1]

Weekly assigned dose	Average weight reduction	Reached at least 5% weight reduction	Did not reach 5%, calculated from the reported percentage
5 mg	15.0%	85%	About 15%
10 mg	19.5%	89%	About 11%
15 mg	20.9%	91%	About 9%

These are trial outcomes over 72 weeks, including treatment discontinuation in the analysis. They are not a test that identifies why one person's treatment is underperforming. A result below 5% also does not necessarily mean zero weight change or zero glucose benefit.

Calculate your own change consistently: (starting weight minus current weight) divided by starting weight, multiplied by 100. For example, a change from 240 to 228 pounds is 5%. Record dates alongside weights so the comparison has a clear time window.

Can a slow responder catch up?

Yes. A 2025 SURMOUNT-1 analysis examined 1,545 participants who took at least 75% of assigned doses and had the required follow-up weights. Of the 278 who had lost less than 5% at week 12, 70% reached at least 5% by week 24 and 90% by week 72. The average time for late responders to reach 5% was approximately 25 weeks. [2]

That analysis selected people with substantial treatment exposure and available follow-up data. It supports allowing time for an effective, tolerated plan to work; it does not mean every slow responder should continue unchanged indefinitely.

A separate 2026 analysis of SURMOUNT-1 and SURMOUNT-2 classified response at week eight. Both early and non-early responders achieved meaningful weight and cardiometabolic improvements by week 72, although early responders improved more on average. [5]

Does a dose below 10 mg mean treatment is inadequate?

No. Zepbound's labeled weight-management maintenance doses are 5, 10 or 15 mg weekly. The 2.5 mg starting dose is used for initiation. Dose selection considers response and tolerability, with increases spaced by at least four weeks. [4]

The SURMOUNT-1 results show why 5 mg should not be dismissed as an ineffective dose. Higher assigned doses produced greater average loss, but treatment does not require every person to reach 15 mg. [1]

At follow-up, record the actual dose history: four weeks at a starting dose plus two weeks at the next dose is different from several months at a stable maintenance dose. If side effects have repeatedly interrupted treatment, the calendar alone can exaggerate how much treatment you have received.

What should be checked when weight is not changing?

Bring a short record that makes the pattern easy to assess:

Information to bring	What it helps clarify
Starting weight, current weight and dated intermediate readings	Whether the issue is a slow trend, fluctuation or a sustained plateau
Dose and date of each change	How long the current regimen has actually been used
Missed injections or supply interruptions	Whether treatment exposure matches the intended plan
Appetite, meals, drinks and activity	Which practical changes are sustainable and where support is needed
Side effects and other medicines	Whether tolerability or another treatment is affecting the plan
Glucose results when diabetes is present	Benefits that a weight-only comparison would miss

Review injection technique with the instructions for the actual pen or vial. Rotate injection sites as directed and check that the product has been stored according to its specific instructions. Different presentations have different handling details, so use the leaflet supplied with that product. [3]

Dietary and activity support remain part of treatment. A brief food and drink record can reveal patterns that are difficult to recall during an appointment. The objective is to find a manageable adjustment, not to explain every slow response as a lack of effort. [6]

Which medical factors deserve attention?

Diabetes changes the comparison. In SURMOUNT-2, adults with type 2 diabetes had average reductions of 12.8% with 10 mg and 14.7% with 15 mg at 72 weeks. Approximately 79% to 83% reached at least 5%. These averages were lower than those in the separate trial without diabetes, but still represented substantial treatment effects. [7]

Other medicines can influence weight. Review insulin, sulfonylureas, corticosteroids and relevant psychiatric medicines with the clinician managing them. Obesity guidelines support considering weight effects when choosing among suitable treatments; this is a medication review, not a reason to stop a necessary prescription independently. [8]

Endocrine testing should answer a specific question. European Society of Endocrinology guidance recommends thyroid-function assessment in obesity, beginning with TSH and adding appropriate tests when abnormal. It advises against routine testing for excess cortisol without clinical suspicion. A broad hormone panel is not a required way to prove tirzepatide non-response. [9]

You can raise these issues early. There is no requirement to wait six months before reporting symptoms, checking an injection problem or reviewing a medicine that changed recently.

When should the treatment plan change?

UK NICE guidance provides a defined review point: if weight reduction remains below 5% after six months on the highest tolerated tirzepatide dose, discuss whether continuing is worthwhile for that person. This is a UK treatment-review recommendation, not a universal definition of biological resistance or a requirement to delay earlier care. [10]

The discussion can cover dose adjustment, an alternative medication, additional nutrition or behavioral support, and specialist obesity care. Bariatric surgery may be another appropriate option depending on the person's health and treatment goals. [6,10]

Do not use a forum rating or someone else's injection schedule as the decision rule. Your record needs to show what was taken, for how long, what changed and what made treatment difficult.

Would semaglutide work better?

The SURMOUNT-5 head-to-head trial randomized 751 adults with obesity without diabetes. At 72 weeks, average weight reduction was 20.2% with maximum tolerated tirzepatide versus 13.7% with maximum tolerated semaglutide. This comparison favors tirzepatide on average; it does not predict the best medication for every individual. [11]

A 2026 matched electronic-record study also found greater average loss with tirzepatide, but its observational design differs from a randomized comparison. Treatment choice still needs to consider the individual's response, access and tolerability. [12]

What can eating-behavior research add?

Appetite, emotional eating and meal organization are useful topics at follow-up. A 2026 study using the EFCA eating-behavior scale examined 66 early responders receiving several obesity medicines. Because it selected people already responding, it cannot tell us who will fail tirzepatide. Its practical contribution is to encourage discussion of eating patterns alongside weight measurements. [13]

When should you seek care sooner?

Severe or persistent abdominal pain, especially with vomiting, or ongoing vomiting with dehydration needs prompt medical assessment. These symptoms should not be treated as an ordinary weight plateau. Pancreatic, gallbladder and dehydration-related problems are addressed in the prescribing information. [3]